Akrikhin Has Launched a Line of Ophthalmology Products


According to statistical data for 2019, glaucoma ranks the fifth1 among the most common eye diseases in the Russian Federation. Besides, in Russia glaucoma is the root cause of disability for poor eyesight. We distinguish two forms of glaucoma: open-angle and angle-closure glaucoma. Open-angle glaucoma is the most prevalent and accounts for more than 80% of all cases. It generally affects people after 40 years of age and may cause irreversible vision loss. The major risk factor for glaucoma development is high intraocular pressure, therefore reducing it remains the only glaucoma treatment strategy that has proven effective2. It is impossible to stop the vision loss process completely, however specialists aim at achieving remission in patients. It requires advanced and available therapies to be prescribed.

Medications for the treatment of open-angle glaucoma and ocular hypertension are the core of Akrikhin’s new ophthalmology portfolio. These include eye drops free of preservatives which may have a negative impact on patients’ quality of life, compliance, as well the results of diagnosis and outcomes of glaucoma-related surgeries: Brim Antiglau ECO (Brimonidine 2 mg/mL), DorAntiglau ECO (Dorzolamide 20 mg/mL), and fixed combinations, such as: DortimolAntiglau ECO (Dorzolamide 20 mg/mL + Timolol 5 mg/mL), BimicombiAntiglau ECO (Bimatoprost 0.3 mg/mL + Timolol 5 mg/mL). Through this, Akrikhin has expanded physicians’ capabilities in practical use of therapeutic drugs for open-angle glaucoma and ocular hypertension depending on the disease stage and counter-indications.

The new line of products offered by Akrikhin also includes therapeutic drugs, such as eye drops Floxepol (Moxifloxacin) 0.5 % for bacterial conjunctivitis, and eye drops Oloftadin ECO (Olopatadine) 1 mg/mL for allergic conjunctivitis, which is free of the preservative benzalkonium chloride. The launch of these products was predetermined by Russian annual statistics which shows that the prevalence of conjunctivitis amounts to around 12 million people, with 60 to 80 % attributable to elderly population.3

Taking full advantage of the visual function requires adequate eye care, especially if there are potential risks of eyesight impairment. Other than hereditary signs, for young people these risks may include external negative factors, such as everyday continuous work at the computer, watching TV or reading too much, driving in the dark, frequent stays in heavily smoked rooms and smoking itself, as well as exposure to intense sunlight. People older than 40 years may have their vision impaired due to age. To maintain vision in both of the categories, Akrikhin offers biologically active dietary supplement SuperOptic in packs of 30 and 60 capsules. THIS PRODUCT IS CLASSIFIED AS BADS AND IS NOT A DRUG.

Ophthalmology products by Akrikhin are available in Russian pharmacies.

1 Ministry of Health of the Russian Federation, Moscow, 2019

2 European Guidelines for Glaucoma, 4th Edition, 2014, p. 152

3 Eye Diseases / Edited by Professor V. G. Kopayeva. Moscow, Ophthalmology, 2018, p. 495.

We use cookies to improve your experience on our site and to show you personalised advertising. By pressing “I AGREE” you accept our cookies policy.
To find out more, go to cookies policy.